Future oncology最新文献_第10页

Multimodality high-frequency ultrasound in the evaluation of cervical malignant lymphoma before biopsy. 多模态高频超声在活检前评估宫颈恶性淋巴瘤的应用

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-20 DOI: 10.1080/14796694.2024.2430168

Hongyan Deng, Kunpeng Cao, Xinhua Ye, Wenjuan Lu, Wenqin Chen, Ya Yuan, Yasu Zhou, Hua Shu

引用次数: 0

Research progress on the role of lipoxygenase and its inhibitors in prostate cancer. 关于脂氧合酶及其抑制剂在前列腺癌中的作用的研究进展。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-13 DOI: 10.1080/14796694.2024.2419356

Xiaobing Li, Jingxin Mao

引用次数: 0

A plain language summary about a cell cycle-based, new surveillance mechanism against cancer. 用通俗易懂的语言概述了一种基于细胞周期的新型癌症监控机制。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1080/14796694.2024.2402649

Albert Qin

引用次数: 0

Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer. 评估 CDK4/6 抑制剂在有症状和无症状转移性乳腺癌患者中的一线应用。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1080/14796694.2024.2432850

İrem Öner, Alper Türkel, Hicran Anık, Ülkü Yalçıntaş Arslan, Cengiz Karaçin

{"title":"Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer.","authors":"İrem Öner, Alper Türkel, Hicran Anık, Ülkü Yalçıntaş Arslan, Cengiz Karaçin","doi":"10.1080/14796694.2024.2432850","DOIUrl":"10.1080/14796694.2024.2432850","url":null,"abstract":"Background: This study aimed to compare the efficacy of CDK4/6 inhibitors plus endocrine therapy in two groups of patients with HR-positive/HER2-negative metastatic breast cancer: those with symptomatic, high tumor burden disease and those with asymptomatic disease.Design and methods: This retrospective study included 193 patients who received either ribociclib or palbociclib in combination with first-line ET. Patients were divided into symptomatic and asymptomatic groups and compared regarding baseline characteristics and progression-free survivals (PFS).Results: Symptomatic patients had a significantly shorter mPFS than asymptomatic patients (22.7 months vs. 35.0 months, p = 0.009). Among symptomatic patients, those treated with ribociclib had a longer mPFS than those treated with palbociclib (28.26 months vs. 17.18 months, p = 0.021). Multivariate analysis identified the symptomatic disease and liver metastasis as independent predictors of shorter mPFS (HR; 1.835, 95% CI; 1.146-2.939 and HR; 2.433, 95% CI; 1.329-4.454, respectively).Conclusion: Our analysis revealed that although symptomatic individuals who underwent CDK4/6 inhibitor plus ET experienced a significant reduction in mPFS durations compared to asymptomatic patients, the 22-month mPFS indicated that CDK4/6 inhibitor plus ET is an effective treatment option.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3443-3450"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma. 关于伊沙妥昔单抗联合卡非佐米、来那度胺和地塞米松治疗高风险新诊断多发性骨髓瘤患者的纯文字摘要。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-09-30 DOI: 10.1080/14796694.2024.2402639

Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hanel, Marc S Raab, Christoph Mann, Markus Munder, Hans Christian Reinhardt, Axel Nogai, Martin Gorner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hermann Einsele, Anna Jauch, Michael Hundemer, Manola Zago, Ema Pozek, Axel Benner, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C Weisel

引用次数: 0

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. 西曲拉替尼治疗分子改变的实体瘤患者：Ib期研究结果。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-08 DOI: 10.1080/14796694.2024.2418285

Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, Sanjay Goel, Rebecca Heist, Theresa L Werner, Keith D Eaton, Judy S Wang, Shubham Pant, Douglas R Adkins, Collin M Blakely, Xiaohong Yan, Saskia Neuteboom, James G Christensen, Richard Chao, Todd Bauer

{"title":"Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.","authors":"Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, Sanjay Goel, Rebecca Heist, Theresa L Werner, Keith D Eaton, Judy S Wang, Shubham Pant, Douglas R Adkins, Collin M Blakely, Xiaohong Yan, Saskia Neuteboom, James G Christensen, Richard Chao, Todd Bauer","doi":"10.1080/14796694.2024.2418285","DOIUrl":"10.1080/14796694.2024.2418285","url":null,"abstract":"Aim: We report clinical activity and safety of sitravatinib in patients with advanced cancer from basket cohorts with specific molecular alterations, in a Phase Ib study.Materials & methods: Patients with advanced solid tumors harboring amplification, mutation, or rearrangement of MET, AXL, RET, NTRK, DDR2, KDR, PDGFRA, KIT or CBL received sitravatinib once daily. Primary end point was confirmed objective response rate (ORR).Results: In total, 113 patients were enrolled following a median of 3 (range 1-18) prior systemic regimens. Altered RET (n = 31), CBL (n = 31) and MET (n = 17) were most frequent cohorts. Overall, 68.9% had reduced tumor volume and most (61.5%) had a best objective response of stable disease. ORR was highest in patients with RET-rearranged non-small cell lung cancer (21.1%) but did not differ significantly from the null hypothesis (ORR ≤15%; p = 0.316). Median progression-free survival and overall survival (5.7 and 24.2 months, respectively) were also longest in the RET-rearranged non-small cell lung cancer cohort. Diarrhea (61.1%), fatigue (50.4%) and hypertension (46.9%) were the most frequent treatment-emergent adverse events. Most treatment-emergent adverse events were mild-to-moderate in severity. The study closed before the planned number of patients were enrolled in all cohorts.Conclusion: Sitravatinib had a manageable safety profile with modest signals of clinical activity in patients with molecularly selected solid tumors.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02219711.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3213-3227"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colorectal cancer research priorities in Uganda: perspectives from local key experts and stakeholders. 乌干达结直肠癌研究的优先事项：当地主要专家和利益相关者的观点。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-25 DOI: 10.1080/14796694.2024.2416885

Nicholas Matovu, Noleb Mugume Mugisha, Alfred Jatho, Charlene M McShane

{"title":"Colorectal cancer research priorities in Uganda: perspectives from local key experts and stakeholders.","authors":"Nicholas Matovu, Noleb Mugume Mugisha, Alfred Jatho, Charlene M McShane","doi":"10.1080/14796694.2024.2416885","DOIUrl":"10.1080/14796694.2024.2416885","url":null,"abstract":"The incidence of colorectal cancer (CRC) is increasing in Uganda but there is limited local research to guide policy and programming for CRC prevention and control. A stakeholder engagement workshop took place in Kampala on 19 March 2024 to identify challenges and opportunities for CRC prevention and control in Uganda. A total of 30 stakeholders with expertise in CRC primary and secondary prevention, diagnosis, treatment, palliative care as well as cancer survivors participated in the workshop. Key challenges for primary prevention included low knowledge/awareness of CRC among the general population and health workers, and rising prevalence of CRC related risk factors. Limited CRC screening, diagnostic facilities and specialists were identified as barriers to diagnosis. Treatment related challenges included limited accessibility to surgical services and drugs, late-stage presentation leading to poor treatment response, treatment abandonment and drug related toxicity. Lack of universal health coverage policies, limited community-based cancer awareness programs, and lack of national cancer registries were cited as policy and economics challenges. Opportunities to address these challenges were discussed. Our findings highlight areas for further research and prioritization to address Uganda's growing CRC burden and may be applicable to other low-resource settings.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3169-3177"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Homologous recombination deficiency in pancreatic neuroendocrine tumors. 胰腺神经内分泌肿瘤的同源重组缺陷

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/14796694.2024.2421160

Camilla Bardasi, Elena Tenedini, Lia Bonamici, Stefania Benatti, Luca Reggiani Bonetti, Gabriele Luppi, Laura Cortesi, Enrico Tagliafico, Massimo Dominici, Fabio Gelsomino

{"title":"Homologous recombination deficiency in pancreatic neuroendocrine tumors.","authors":"Camilla Bardasi, Elena Tenedini, Lia Bonamici, Stefania Benatti, Luca Reggiani Bonetti, Gabriele Luppi, Laura Cortesi, Enrico Tagliafico, Massimo Dominici, Fabio Gelsomino","doi":"10.1080/14796694.2024.2421160","DOIUrl":"10.1080/14796694.2024.2421160","url":null,"abstract":"Aim: Pancreatic Neuroendocrine tumors (pNETs) are a heterogeneous group of neoplasms whose tumor biology is still little known. Thanks to next-generation sequencing, pathogenic mutations in base-excision-repair MUTYH gene and homologous recombination genes CHEK2 and BRCA2 seem to have a role in the development of pNETs.Research design & methods: We assumed that Homologous Recombination Deficiency (HRD) could be a critical pathogenetic mechanism for pNETs. We evaluated the HR status in a case series of 33 patients diagnosed with pNET at the Modena Cancer Center using the AmoyDX HRD Focus assay.Results: The AmoyDx test did not identify any HRD-positive patients (median GSS equal to 1.1, positive score: >50), and no pathogenic BRCA variants were detected. However, thanks to the SNP analysis, a consistent number of partial or complete single-copy deletions or duplications in several chromosomes.Conclusion: The AmoyDX HRD focus assay performed well on pancreatic samples, despite being originally designed for ovarian cancer and used on samples stored for over a year. Larger studies are needed to further assess the role of HRD assays in pNETs research.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3257-3266"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer. 利用生物信息学和人工智能绘制乳腺癌细胞周期蛋白依赖性激酶 4/6 抑制剂生物标志物图谱。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-12 DOI: 10.1080/14796694.2024.2419352

Kim Wager, Yao Wang, Andrew Liew, Dean Campbell, Feng Liu, Jean-François Martini, Niusha Ziaee, Yuan Liu

{"title":"Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer.","authors":"Kim Wager, Yao Wang, Andrew Liew, Dean Campbell, Feng Liu, Jean-François Martini, Niusha Ziaee, Yuan Liu","doi":"10.1080/14796694.2024.2419352","DOIUrl":"10.1080/14796694.2024.2419352","url":null,"abstract":"A cyclin-dependent kinase 4/6 (CDK4/6) inhibitor combined with endocrine therapy is the standard-of-care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. However, not all patients respond to the treatment, resistance often occurs and efficacy outcomes from early breast cancer trials have been mixed. To identify biomarkers associated with CDK4/6 inhibitor response or resistance, we combined bioinformatic-database analyses, artificial intelligence-assisted literature review, and manual literature review (Embase and OVID Medline; search window: January 2012-October 2022) to compile data to comprehensively describe the CDK4/6 inhibitor biomarker landscape. Based on these results, and validation by external experts, we identified 15 biomarkers of clinical importance (AR , AURKA, ERBB2, ESR1, CCNE1, CDKN1A/B, CDK2, CDK6, CDK7, CDK9, FGFR1/2, MYC, PIK3CA/AKT, RB1 and STAT3) that could guide future breast cancer research.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3519-3537"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Part 1 - Highlights of the San Antonio Breast Cancer Symposium 2023. 第 1 部分 - 2023 年圣安东尼奥乳腺癌研讨会要点。

IF 3 4区医学

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-10-29 DOI: 10.1080/14796694.2024.2418804

John R Benson, Ismail Jatoi

引用次数: 0